SIGNUS USA launches U.S. clinical debut of VertaConnect implant

SIGNUS USA announced the first U.S. surgery using its VertaConnect expandable lumbar spine implant, performed July 3 at Sarasota Memorial Hospital in Florida. The milestone marks the clinical debut of SIGNUS technology in the American market and signals a push to reach more spine surgeons with a new TLIF device.

Why it matters: - SIGNUS USA is now in the U.S. market with a live clinical case behind its VertaConnect lumbar implant. - The first surgery gives the company a concrete entry point with surgeons and hospitals considering expandable spine technology. - The milestone could help the Germany-based spinal implant maker build credibility with American spine specialists.

What happened: - SIGNUS USA announced the first U.S. surgery using the VertaConnect spinal implant system. - Dr. Ngoc-Lam M. Nguyen performed the procedure on July 3, 2026, at Sarasota Memorial Hospital in Florida. - The surgery marked the official clinical debut of SIGNUS technology in the United States.

The details: - VertaConnect is a next-generation transforaminal lumbar interbody fusion, or TLIF, implant. - The system is designed for both traditional open procedures and endoscopic approaches. - The implant features an expandable design, a large contact surface and an open architecture. - SIGNUS says those features are intended to support stability, osseointegration and spinal alignment through a streamlined surgical approach. - SIGNUS USA is the U.S. subsidiary of SIGNUS Medizintechnik GmbH, a Germany-based family-owned company. - SIGNUS Medizintechnik says it has more than 30 years of experience in spinal implant design, manufacturing and innovation. - The company says it is using that background to offer surgeon-focused solutions to the U.S. spine community. - More information is available on the company's U.S. site.

Between the lines: - The first U.S. surgery is a commercial and clinical proof point, not just a product announcement. - A successful initial case can matter in spine care, where surgeon confidence and operating-room familiarity often shape adoption. - The U.S. launch also shows SIGNUS is trying to translate its European track record into a more competitive American market.

What's next: - SIGNUS USA will likely use this first case to support broader surgeon outreach and market adoption. - Additional U.S. cases would help establish how VertaConnect performs outside its debut procedure. - The company is positioning itself to expand its presence with more advanced implant offerings for American spine surgeons.